1.Smear-positive pulmonary tuberculosis patients with previously abnormal chest radiographs: missed opportunities for early diagnosis.
Lovel Corpuz GALAMAY ; Cynthia Bin Eng CHEE ; Kyi Win KHIN MAR ; Bih Qin LAU ; Yee Tang WANG
Singapore medical journal 2021;62(6):296-299
INTRODUCTION:
It is vital to diagnose and treat pulmonary tuberculosis (PTB) early, in the interests of the patient and public health. At the Singapore Tuberculosis Control Unit (TBCU), it was not uncommon to discover abnormal chest radiographs (CXRs) predating their PTB diagnosis by months to years in the electronic medical records (EMRs) of sputum acid-fast bacilli smear-positive patients. Our study explored this observation.
METHODS:
The EMRs of sputum smear-positive PTB patients treated at the TBCU from January to July 2014 were viewed for abnormal CXRs preceding their PTB diagnosis. Information in the EMRs pertaining to the indication for the CXRs, radiological reports (including whether the possibility of PTB was stated) and action taken was captured.
RESULTS:
Of the 254 sputum smear-positive patients, 108 had previous CXRs in their EMRs, of whom 39 (36.1%) had previous CXRs compatible with PTB. Most of these were performed in tertiary institutions and for reasons unrelated to PTB. No action was taken in response to these CXRs in 24 (61.5%) patients. 27 (69.2%) patients had abnormal CXRs dating back more than six months, with 12 (30.8%) dating back more than 30 months before the PTB diagnosis. Patients aged ≥ 55 years were significantly more likely to have previous CXRs that were compatible with PTB.
CONCLUSION
PTB patients may be asymptomatic or have chronic indolent disease and remain undiagnosed for years. There is a need for vigilance within our healthcare system to seize opportunities for early diagnosis and treatment to prevent the spread of this infectious disease in Singapore.
2.Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic.
Jason Pik Eu CHANG ; Yu Jun WONG ; Wei Lyn YANG ; Kieron Boon Leng LIM ; Poh Seng TAN ; Gim Hin HO ; Benjamin Cherng Hann YIP ; James Weiquan LI ; Chern Hao CHONG ; David Eng Hui ONG ; Tju Siang CHUA ; Charles Kien Fong VU ; Kok Ann GWEE ; Tiing Leong ANG ; Chee Kiat TAN
Singapore medical journal 2020;61(12):619-623
In this paper, we aim to provide professional guidance to clinicians who are managing patients with chronic liver disease during the current coronavirus disease 2019 (COVID-19) pandemic in Singapore. We reviewed and summarised the available relevant published data on liver disease in COVID-19 and the advisory statements that were issued by major professional bodies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, contextualising the recommendations to our local situation.
COVID-19/epidemiology*
;
Carcinoma, Hepatocellular/therapy*
;
Chronic Disease
;
Hepatitis B, Chronic/therapy*
;
Hepatitis C, Chronic/therapy*
;
Humans
;
Liver Cirrhosis/therapy*
;
Liver Diseases/therapy*
;
Liver Neoplasms/therapy*
;
Liver Transplantation
;
Singapore/epidemiology*
3.Current Status and Growth of Nuclear Theranostics in Singapore
Hian Liang HUANG ; Aaron Kian Ti TONG ; Sue Ping THANG ; Sean Xuexian YAN ; Winnie Wing Chuen LAM ; Kelvin Siu Hoong LOKE ; Charlene Yu Lin TANG ; Lenith Tai Jit CHENG ; Gideon Su Kai OOI ; Han Chung LOW ; Butch Maulion MAGSOMBOL ; Wei Ying THAM ; Charles Xian Yang GOH ; Colin Jingxian TAN ; Yiu Ming KHOR ; Sumbul ZAHEER ; Pushan BHARADWAJ ; Wanying XIE ; David Chee Eng NG
Nuclear Medicine and Molecular Imaging 2019;53(2):96-101
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
Hope
;
Humans
;
Lutetium
;
Membranes
;
Nuclear Medicine
;
Prostate
;
Radium
;
Receptors, Peptide
;
Singapore
;
Theranostic Nanomedicine
;
Yttrium
4.Overview of Urethral Reconstruction by Tissue Engineering: Current Strategies, Clinical Status and Future Direction
Zahra RASHIDBENAM ; Mohd Hafidzul JASMAN ; Pezhman HAFEZ ; Guan Hee TAN ; Eng Hong GOH ; Xeng Inn FAM ; Christopher Chee Kong HO ; Zulkifli Md ZAINUDDIN ; Reynu RAJAN ; Fatimah MOHD NOR ; Mohamad Aznan SHUHAILI ; Nik Ritza KOSAI ; Farrah Hani IMRAN ; Min Hwei NG
Tissue Engineering and Regenerative Medicine 2019;16(4):365-384
BACKGROUND: Urinary tract is subjected to a variety of disorders such as urethral stricture, which often develops as a result of scarring process. Urethral stricture can be treated by urethral dilation and urethrotomy; but in cases of long urethral strictures, substitution urethroplasty with genital skin and buccal mucosa grafts is the only option. However a number of complications such as infection as a result of hair growth in neo-urethra, and stone formation restrict the application of those grafts. Therefore, tissue engineering techniques recently emerged as an alternative approach, aiming to overcome those restrictions. The aim of this review is to provide a comprehensive coverage on the strategies employed and the translational status of urethral tissue engineering over the past years and to propose a combinatory strategy for the future of urethral tissue engineering. METHODS: Data collection was based on the key articles published in English language in years between 2006 and 2018 using the searching terms of urethral stricture and tissue engineering on PubMed database. RESULTS: Differentiation of mesenchymal stem cells into urothelial and smooth muscle cells to be used for urologic application does not offer any advantage over autologous urothelial and smooth muscle cells. Among studied scaffolds, synthetic scaffolds with proper porosity and mechanical strength is the best option to be used for urethral tissue engineering. CONCLUSION: Hypoxia-preconditioned mesenchymal stem cells in combination with autologous cells seeded on a prevascularized synthetic and biodegradable scaffold can be said to be the best combinatory strategy in engineering of human urethra.
Cicatrix
;
Data Collection
;
Hair
;
Humans
;
Mesenchymal Stromal Cells
;
Mouth Mucosa
;
Myocytes, Smooth Muscle
;
Porosity
;
Skin
;
Tissue Engineering
;
Transplants
;
Urethra
;
Urethral Stricture
;
Urinary Tract
5.Current Status and Growth of Nuclear Theranostics in Singapore
Hian Liang HUANG ; Aaron Kian Ti TONG ; Sue Ping THANG ; Sean Xuexian YAN ; Winnie Wing Chuen LAM ; Kelvin Siu Hoong LOKE ; Charlene Yu Lin TANG ; Lenith Tai Jit CHENG ; Gideon Su Kai OOI ; Han Chung LOW ; Butch Maulion MAGSOMBOL ; Wei Ying THAM ; Charles Xian Yang GOH ; Colin Jingxian TAN ; Yiu Ming KHOR ; Sumbul ZAHEER ; Pushan BHARADWAJ ; Wanying XIE ; David Chee Eng NG
Nuclear Medicine and Molecular Imaging 2019;53(2):96-101
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
6.Ministry of Health Clinical Practice Guidelines: Chronic Obstructive Pulmonary Disease.
Tow Keang LIM ; Cynthia B CHEE ; Patsy CHOW ; Gerald Sw CHUA ; Soo Kiang ENG ; Soon Keng GOH ; Kwee Keng KNG ; Wai Hing LIM ; Tze Pin NG ; Thun How ONG ; S T Angeline SEAH ; Hsien Yung TAN ; K H TEE ; Vimal PALANICHAMY ; Meredith T YEUNG
Singapore medical journal 2018;59(2):76-86
The Ministry of Health (MOH) has updated the Clinical Practice Guidelines on Chronic Obstructive Pulmonary Disease (COPD) to provide doctors and patients in Singapore with evidence-based treatment for COPD. This article reproduces the introduction and executive summary (with recommendations from the guidelines) from the MOH Clinical Practice Guidelines on COPD, for the information of SMJ readers. Chapters and page numbers mentioned in the reproduced extract refer to the full text of the guidelines, which are available from the Ministry of Health website: https://www.moh.gov.sg/content/moh_web/healthprofessionalsportal/doctors/guidelines/cpg_medical.html. The recommendations should be used with reference to the full text of the guidelines. Following this article are multiple choice questions based on the full text of the guidelines.
Adult
;
Aged
;
Evidence-Based Medicine
;
Humans
;
Middle Aged
;
Palliative Care
;
Prevalence
;
Pulmonary Disease, Chronic Obstructive
;
diagnosis
;
therapy
;
Pulmonary Medicine
;
standards
;
Quality Improvement
;
Radiography, Thoracic
;
Risk Factors
;
Singapore
;
Steroids
;
therapeutic use
7.Lipid management in Diabetes Mellitus: A Singapore Perspective
The Singapore Family Physician 2017;43(1):7-9
Patients with Diabetes Mellitus (DM) have increased risk of atherosclerosis and up to half die during the first myocardial infarction. Primary prevention of cardiovascular disease (CVD) should be a major goal in the management of DM patients. DM patients with the highest risk (established CVD or chronic kidney disease) should have aggressive lipid-lowering therapy. Statin therapy should be the first line of therapy for all DM patients with elevated LDL-C. Ezetimibe can be added if LDL-C target is not reached at maximally tolerated statin dose. Fibrates can be used in DM patients with TG of >4.5 mmol/l (400 mg/dl). The adverse effects from lipid-lowering therapy are low while the benefits of intervention are well proven and significant.
8.Therapeutic temperature management (TTM): post-resuscitation care for adult cardiac arrest, with recommendations from the National TTM Workgroup.
Siew Hon Benjamin LEONG ; Enoch CHAN ; Benjamin Choon Heng HO ; Colin YEO ; Sennen LEW ; Duu Wen SEWA ; Shir Lynn LIM ; Chee Wan LEE ; Pow Li CHIA ; Tien Siang Eric LIM ; Eng Kiang LEE ; Marcus Eng Hock ONG
Singapore medical journal 2017;58(7):408-410
Therapeutic temperature management (TTM) was strongly recommended by the 2015 International Liaison Committee on Resuscitation as a component of post-resuscitation care. It has been known to be effective in improving the survival rate and neurologic functional outcome of patients after cardiac arrest. In an effort to increase local adoption of TTM as a standard of post-resuscitation care, this paper discusses and makes recommendations on the treatment for local providers.
9.Ministry of Health Clinical Practice Guidelines: Lipids.
E Shyong TAI ; Boon Lock CHIA ; Amber Carla BASTIAN ; Terrance CHUA ; Sally Chih Wei HO ; Teck Siew KOH ; Lip Ping LOW ; Jeannie S TEY ; Kian Keong POH ; Chee Eng TAN ; Peter TING ; Tat Yean THAM ; Sue-Anne TOH ; Rob M van DAM
Singapore medical journal 2017;58(3):155-166
The Ministry of Health (MOH) has updated the Clinical Practice Guidelines on Lipids to provide doctors and patients in Singapore with evidence-based treatment for lipids. This article reproduces the introduction and executive summary (with recommendations from the guidelines) from the MOH Clinical Practice Guidelines on Lipids, for the information of SMJ readers. Chapters and page numbers mentioned in the reproduced extract refer to the full text of the guidelines, which are available from the Ministry of Health website: http://www.moh.gov.sg/content/moh_web/healthprofessionalsportal/doctors/guidelines/cpg_medical.html.
Adult
;
Cardiovascular Diseases
;
complications
;
therapy
;
Child
;
Coronary Artery Disease
;
complications
;
therapy
;
Decision Support Systems, Clinical
;
Dyslipidemias
;
blood
;
complications
;
therapy
;
Evidence-Based Medicine
;
Female
;
Humans
;
Kidney Failure, Chronic
;
complications
;
therapy
;
Life Style
;
Lipids
;
blood
;
Lipoproteins, LDL
;
blood
;
Male
;
Practice Guidelines as Topic
;
Pregnancy
;
Pregnancy Complications
;
Risk Assessment
;
Risk Factors
;
Singapore
10.Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade.
Chee Keong TOH ; Whee Sze ONG ; Daniel Sw TAN ; Quan Sing NG ; Ravindran KANESVARAN ; Kam Weng FONG ; Mei Kim ANG ; Eng Huat TAN ; Wan Teck LIM
Annals of the Academy of Medicine, Singapore 2017;46(9):333-338
INTRODUCTIONWe reviewed changes in clinical characteristics, treatment and survival of lung cancer patients in Singapore over the past decade.
MATERIALS AND METHODSWe reviewed all primary lung cancer cases from January 2004 to December 2013. Basic demographic, clinical and treatment data were extracted from the database. Overall survival (OS) was calculated using Kaplan-Meier method; survival curves were compared using log-rank test. Linear regression trend lines were estimated using least squares approach, and Cox regression analyses were performed to identify prognostic factors.
RESULTSAmong 6006 lung cancer patients, the median age was 68 years old, 65% were males, 88% were Chinese, 92% had non-small-cell lung cancer and 76% had advanced stage IIIB/IV. There were proportionally more adenocarcinomas diagnosed over the years, while that of squamous cell carcinoma (SCC) and small-cell-lung cancer (SCLC) have remained stable. The median OS of all patients increased from 9.2 months in 2004 to 11.5 months in 2013. This survival improvement was statistically significant among patients with stage IIIB/IV (6.7 to 8.7 months;= 0.005) and adenocarcinoma (12.7 to 15.4 months;= 0.041). There was no improvement in median OS for SCC or SCLC. The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) (hazard ratio [HR] 0.68; 95% CI, 0.63 to 0.73) and pemetrexed (HR, 0.69; 95% CI, 0.63 to 0.76) were significantly associated with improved OS.
CONCLUSIONSurvival of patients with advanced stage IIIB/IV lung adenocarcinoma has improved over the past decade, and is potentially associated with the use of EGFR TKI and pemetrexed.


Result Analysis
Print
Save
E-mail